Potential cardioprotective effect of trimetazidine in mice model of endotoxemia: role of AMPK-Nrf2.

Q4 Medicine

Wiadomosci lekarskie Pub Date : 2025-01-01 DOI:10.36740/WLek/190820

Alaa Kadhum Mosa, Sahar Majeed, Fadhaa Abdulameer Ghafil, Najah Rayish Hadi

{"title":"Potential cardioprotective effect of trimetazidine in mice model of endotoxemia: role of AMPK-Nrf2.","authors":"Alaa Kadhum Mosa, Sahar Majeed, Fadhaa Abdulameer Ghafil, Najah Rayish Hadi","doi":"10.36740/WLek/190820","DOIUrl":null,"url":null,"abstract":"Objective: Aim: To clarify the potential cardioprotective effect of Trimetazidine against experimentally sepsis-caused endotoxic cardiac injury damage in mice.Patients and methods: Materials and Methods: 24 Mice were divided into four groups (n=6): Sham group, CLP group DMSO group, trimetazidine-treated group 50 mg/kg IP, 1hr before CLP, then the animals were sacrificed 24 hr after CLP and tissue sample was taken for measurement of TNF-α, TNF-αr1, IL-1β, HO-1, MPO, caspase-11, F2-isoprostane and serum troponin by ELISA and gene expression of AMPK-Nrf2 by qpcr and histopathological study.Results: Results: trimetazidine treated group showed significant changes as compared with clp group regarding TNF-α, TNF-αr1, IL-1β, HO-1, MPO, CASPASE-11, F2-ISOPROSTANE as well as affect tissue mRNA expression of AMPK-Nrf2 genes p<0.05.Conclusion: Conclusions: We evaluate that Trimetazidine has cardio protective effects due to its anti-inflammatory and anti-oxidative action. Also, trimetazidine showed a cardio-protective effect as they affect tissue mRNA expression of AMPK-Nrf2 genes.","PeriodicalId":23643,"journal":{"name":"Wiadomosci lekarskie","volume":"78 1","pages":"35-44"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiadomosci lekarskie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36740/WLek/190820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Aim: To clarify the potential cardioprotective effect of Trimetazidine against experimentally sepsis-caused endotoxic cardiac injury damage in mice.

Patients and methods: Materials and Methods: 24 Mice were divided into four groups (n=6): Sham group, CLP group DMSO group, trimetazidine-treated group 50 mg/kg IP, 1hr before CLP, then the animals were sacrificed 24 hr after CLP and tissue sample was taken for measurement of TNF-α, TNF-αr1, IL-1β, HO-1, MPO, caspase-11, F2-isoprostane and serum troponin by ELISA and gene expression of AMPK-Nrf2 by qpcr and histopathological study.

Results: Results: trimetazidine treated group showed significant changes as compared with clp group regarding TNF-α, TNF-αr1, IL-1β, HO-1, MPO, CASPASE-11, F2-ISOPROSTANE as well as affect tissue mRNA expression of AMPK-Nrf2 genes p<0.05.

Conclusion: Conclusions: We evaluate that Trimetazidine has cardio protective effects due to its anti-inflammatory and anti-oxidative action. Also, trimetazidine showed a cardio-protective effect as they affect tissue mRNA expression of AMPK-Nrf2 genes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiadomosci lekarskie Medicine-Medicine (all)

CiteScore

0.80

自引率

0.00%

发文量

482